These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 4838914

  • 1. Attempted use of haloperidol in the treatment of L-dopa induced dyskinesias.
    Klawans HL, Weiner WJ.
    J Neurol Neurosurg Psychiatry; 1974 Apr; 37(4):427-30. PubMed ID: 4838914
    [Abstract] [Full Text] [Related]

  • 2. [Problems and therapy of L-DOPA-induced dyskinesias].
    Völler GW, Deze J, Gundlach U, Muschard F.
    Nervenarzt; 1972 Nov; 43(11):584-6. PubMed ID: 4564994
    [No Abstract] [Full Text] [Related]

  • 3. Analysis of L-dopa induced dyskinesias in 51 patients with Parkinsonism.
    Mones RJ, Elizan TS, Siegel GJ.
    J Neurol Neurosurg Psychiatry; 1971 Dec; 34(6):668-73. PubMed ID: 5158780
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The treatment of dystonia with L-dopa and haloperidol.
    Mandell S.
    Neurology; 1970 Nov; 20(11):103-6. PubMed ID: 5529471
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Levodopa-induced dyskinesias. Comparison in Parkinsonism-dementia and amyotrophic lateral sclerosis.
    Chase TN, Holden EM, Brody JA.
    Arch Neurol; 1973 Nov; 29(5):328-33. PubMed ID: 4743883
    [No Abstract] [Full Text] [Related]

  • 8. Treatment of Parkinsonism with Laevo-dopa.
    Mawdsley C.
    Br Med J; 1970 Feb 07; 1(5692):331-7. PubMed ID: 4906702
    [Abstract] [Full Text] [Related]

  • 9. Importance and pathogenesis of abnormal movements during L-dopa therapy of Parkinson's disease.
    Barbeau A.
    Neurology; 1970 Apr 07; 20(4):377. PubMed ID: 5534982
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Treatment of Parkinsonism with oral L-DOPA combined with a decarboxylase inhibitor (Ro IV 46.02)].
    Tissot R, Gaillard JM, Guggisberg M, Gauthier G, de Ajuriaguerra J.
    Presse Med (1893); 1969 Apr 05; 77(17):619-22. PubMed ID: 5785081
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Therapeutic guidelines and side effects encountered during L-dopa therapy in 100 cases of parkinsonism.
    Jenkins AC, Schwieger AC.
    Med J Aust; 1971 Oct 02; 2(14):693-700. PubMed ID: 5114186
    [No Abstract] [Full Text] [Related]

  • 20. L-dopa in the treatment of parkinsonism.
    Haleem MA.
    Gerontol Clin (Basel); 1972 Oct 02; 14(4):242-8. PubMed ID: 4634915
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.